Membrane-Based Water for Injection

Individuals take for granted everyday interactions with well-designed products and devices that save both time and aggravation. Well-designed products can eliminate overall confusion for the user. Every day, more medical devices are designed for portability and at home monitoring. A major initiative in the medical device industry is to reduce the workload on our already overworked medical professionals. Medical device manufacturers must consider countless items when designing and manufacturing their final product, but unfortunately, connectors usually take a back seat to other more engaging topics. Nicomatic has relationships with many of the top medical device manufacturers to help them determine the best connector solution for their specific application. In the medical market, connectors are unique to their specific application and one solution does not work across the board.

Innovation continues to be a primary driver of value in pharmaceutical research. However, simultaneously, research budgets are coming under ever-increasing pressure. As a consequence, pharma is moving toward a so-called open research model, one that dispenses with recurrent fixed costs in favor of a more flexible and dynamic external “spend.” By adopting this model, pharma could tap into innovation outside their walls. In this webinar, case studies will be presented highlighting the value of such collaborations, while focusing on discovery campaigns that employ highly relevant functional assays.

Delivery of therapeutics to the human eye is one of the most interesting—but challenging—endeavors a formulator can take on. The anatomy and chemical composition of the eye make it highly resistant to pharmaceutical penetration. Successfully circumventing these protective barriers requires intimate knowledge of ocular delivery as well as specialized development and manufacturing expertise.

Today, there are clear signs that the biopharmaceutical industry is facing a quiet yet potentially damaging force: compressive disruption. However, future-focused biopharma companies have found a way to deliver exceptional growth amidst compressive disruption: by embracing New Science, an ever-evolving combination of the best in science and health technology that is filling unmet need and raising the standard of care. Accenture research finds that leaders in New Science are investing 6-7x more in digital, data and genomics compared to their peers.